search
Back to results

Melatonin Supplements for Improving Sleep in Individuals With Hypertension

Primary Purpose

Sleep Disorders, Hypertension

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Melatonin
Placebo
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Disorders focused on measuring Sleep disorders, High blood pressure

Eligibility Criteria

35 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosed with uncomplicated hypertension Currently being treated with Atenolol (a beta-blocker) Exclusion Criteria: History of medical illness other than essential hypertension Personal or family history of psychiatric illness Current use of any medication other than anti-hypertensive drugs Any recent travel across time zones History of working various shifts on an irregular basis

Sites / Locations

  • Brigham and Women's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)

Placebo

Outcomes

Primary Outcome Measures

Sleep Quality
Sleep efficiency as measured by polysomnography (total time asleep as a percentage of the 8-hour sleep opportunity)

Secondary Outcome Measures

Change in Systolic Blood Pressure
Systolic blood pressure as measured by 24-h ambulatory blood pressure monitoring

Full Information

First Posted
October 11, 2005
Last Updated
October 13, 2017
Sponsor
Brigham and Women's Hospital
Collaborators
National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00238108
Brief Title
Melatonin Supplements for Improving Sleep in Individuals With Hypertension
Official Title
Melatonin Supplementation in Hypertensive Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will evaluate the effectiveness of treatment with melatonin supplements in improving sleep in individuals with high blood pressure who are taking beta-blockers.
Detailed Description
Hypertension, or high blood pressure, is a condition in which an individual's blood pressure is higher than the normal level. It is estimated that one in three individuals in the United States has high blood pressure, though many do not know it because there are usually no symptoms. Uncontrolled hypertension may lead to stroke, heart attack, heart failure, or kidney failure. Beta-blockers are one class of drugs that have been developed to help lower blood pressure, and thereby decrease the risk for these serious problems. Beta-blockers also lower the levels of melatonin, a hormone that has a sleep-promoting effect. Many individuals who take beta-blockers for hypertension complain that they have trouble sleeping, which may be related to the beta-blockers' effect on melatonin levels. This study will evaluate the effectiveness of treatment with melatonin supplements in improving sleep in individuals with high blood pressure who are taking beta-blockers. In addition, the study will examine whether the melatonin supplements aid in lowering blood pressure. Participants in this double-blind study will be randomly assigned to receive either melatonin supplements or placebo for the duration of the study. Participants will take part in two inpatient phases. Each inpatient stay will last 4 days and will be separated by 3 to 4 weeks. While in the clinic, participants' sleep patterns and core temperature will be recorded and plasma, saliva, and urine samples will be collected. Blood pressure will be measured before and after each inpatient stay, as well as at points during the stay. Throughout the study, participants' activity will be monitored by an accelerometer worn around the wrist.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Disorders, Hypertension
Keywords
Sleep disorders, High blood pressure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Melatonin
Other Intervention Name(s)
N-acetyl-5-methoxytryptamine
Intervention Description
2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Sleep Quality
Description
Sleep efficiency as measured by polysomnography (total time asleep as a percentage of the 8-hour sleep opportunity)
Time Frame
Measurement after 3 weeks of supplementation
Secondary Outcome Measure Information:
Title
Change in Systolic Blood Pressure
Description
Systolic blood pressure as measured by 24-h ambulatory blood pressure monitoring
Time Frame
Measurement after 3 weeks of supplementation compared to baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with uncomplicated hypertension Currently being treated with Atenolol (a beta-blocker) Exclusion Criteria: History of medical illness other than essential hypertension Personal or family history of psychiatric illness Current use of any medication other than anti-hypertensive drugs Any recent travel across time zones History of working various shifts on an irregular basis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank AJ Scheer, PhD
Organizational Affiliation
Brigham and Women's Hospital, Harvard Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
14732734
Citation
Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004 Feb;43(2):192-7. doi: 10.1161/01.HYP.0000113293.15186.3b. Epub 2004 Jan 19.
Results Reference
background
PubMed Identifier
23024438
Citation
Scheer FA, Morris CJ, Garcia JI, Smales C, Kelly EE, Marks J, Malhotra A, Shea SA. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. Sleep. 2012 Oct 1;35(10):1395-402. doi: 10.5665/sleep.2122.
Results Reference
derived

Learn more about this trial

Melatonin Supplements for Improving Sleep in Individuals With Hypertension

We'll reach out to this number within 24 hrs